Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality
Annals of Hematology · 20.11.2026
DOI: 10.1007/s00277-026-07374-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 20.11.2026. Verfasst von Jelena Ivanovic und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Ministry of Science, Technological Development and Innovation
Zitieren
APA
Ivanovic, J., Vukovic, V., Miljic, P., & Antic, D. (2026). Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality. Annals of Hematology. https://doi.org/10.1007/s00277-026-07374-6
Vancouver
Ivanovic J, Vukovic V, Miljic P, Antic D. Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality. Annals of Hematology. 2026. doi:10.1007/s00277-026-07374-6
BibTeX
@article{Ivanovic2026,
author = {Ivanovic, Jelena and Vukovic, Vojin and Miljic, Predrag and Antic, Darko},
title = {Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07374-6}
}
EUVIMED